tetano
Editor, Senior Moderator
Eur J Ophthalmol
. 2022 Mar 21;11206721221088439.
doi: 10.1177/11206721221088439. Online ahead of print.
Recurrence of tubercular choroiditis following anti-SARS-CoV-2 vaccination
Atul Arora[SUP] 1 [/SUP], Sabia Handa[SUP] 1 [/SUP], Simar Rajan Singh[SUP] 1 [/SUP], Aman Sharma[SUP] 2 [/SUP], Reema Bansal[SUP] 1 [/SUP], Rupesh Agrawal[SUP] 3 [/SUP], Vishali Gupta[SUP] 1 [/SUP]
Affiliations
Abstract
Purpose: To report recurrence of tubercular choroiditis following anti-SARS-CoV-2 vaccination in two patients with quiescent disease activity for more than a year.
Methods: Retrospective observational case reports.
Results: Two patients (one female and one male) under follow-up for posterior uveitis having stable course with absence of ocular inflammation for more than a year presented with recurrence of choroiditis lesions 2-6 weeks following anti-SARS-CoV-2 vaccination. Both the patients were managed with intravitreal dexamethasone implant (Ozurdex®, Allergan, Inc., Irvine, CA, USA) and showed resolution of choroiditis lesions upon follow-up.
Conclusions: Acute onset recurrence of inflammation, in absence of any change in health status or treatment suggests the potential role of vaccination being the trigger of this reactivation. Given large-scale vaccination against novel coronavirus- SARS-CoV-2, careful vigilance is warranted to pick up the disease recurrence in patients with posterior uveitis.
Keywords: IMMUNOLOGY; RETINA; UVEA; UVEITIS; choroidal/retinal inflammation; immunology; posterior uveitis.
. 2022 Mar 21;11206721221088439.
doi: 10.1177/11206721221088439. Online ahead of print.
Recurrence of tubercular choroiditis following anti-SARS-CoV-2 vaccination
Atul Arora[SUP] 1 [/SUP], Sabia Handa[SUP] 1 [/SUP], Simar Rajan Singh[SUP] 1 [/SUP], Aman Sharma[SUP] 2 [/SUP], Reema Bansal[SUP] 1 [/SUP], Rupesh Agrawal[SUP] 3 [/SUP], Vishali Gupta[SUP] 1 [/SUP]
Affiliations
- PMID: 35306917
- DOI: 10.1177/11206721221088439
Abstract
Purpose: To report recurrence of tubercular choroiditis following anti-SARS-CoV-2 vaccination in two patients with quiescent disease activity for more than a year.
Methods: Retrospective observational case reports.
Results: Two patients (one female and one male) under follow-up for posterior uveitis having stable course with absence of ocular inflammation for more than a year presented with recurrence of choroiditis lesions 2-6 weeks following anti-SARS-CoV-2 vaccination. Both the patients were managed with intravitreal dexamethasone implant (Ozurdex®, Allergan, Inc., Irvine, CA, USA) and showed resolution of choroiditis lesions upon follow-up.
Conclusions: Acute onset recurrence of inflammation, in absence of any change in health status or treatment suggests the potential role of vaccination being the trigger of this reactivation. Given large-scale vaccination against novel coronavirus- SARS-CoV-2, careful vigilance is warranted to pick up the disease recurrence in patients with posterior uveitis.
Keywords: IMMUNOLOGY; RETINA; UVEA; UVEITIS; choroidal/retinal inflammation; immunology; posterior uveitis.